Capricor Therapeutics receives a STRONG SELL rating due to high regulatory risk surrounding its DMD therapy, Deramiocel. Hope-3 trial data reporting is confusing, with p-values for the primary ...
SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...
So hi, everyone. Welcome to today's webinar with PPMD, where we're joined by Capricor Therapeutics, who are providing a community update on their Phase 3 trial, HOPE-3, which was evaluating their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results